Dynavax Technologies

About:

Dynavax Technologies is a biopharmaceutical company discovering and developing novel products to prevent and treat infectious diseases.

Website: http://www.dynavax.com

Top Investors: Hercules Capital, Deerfield, National Institute of Allergy and Infectious Diseases, Bill & Melinda Gates Foundation, Piper Sandler

Description:

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018TM adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.